{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tezacaftor&page=3", "query": { "intervention": "Tezacaftor", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 62, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tezacaftor&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tezacaftor&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T04:35:28.747Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03460990", "title": "A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-659/TEZ/IVA", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 116, "start_date": "2018-05-01", "completion_date": "2018-10-08", "has_results": true, "last_update_posted_date": "2019-10-17", "last_synced_at": "2026-11-15T04:35:28.747Z", "location_count": 28, "location_summary": "Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Boise", "state": "Idaho" }, { "city": "Niles", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03460990" }, { "nct_id": "NCT04537793", "title": "Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "5 Years", "sex": "ALL", "summary": "2 Years to 5 Years" }, "enrollment_count": 83, "start_date": "2020-11-19", "completion_date": "2022-06-03", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-11-15T04:35:28.747Z", "location_count": 13, "location_summary": "Tucson, Arizona • Palo Alto, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04537793" }, { "nct_id": "NCT07437105", "title": "Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-272", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Tezacaftor", "type": "DRUG" }, { "name": "Deutivacaftor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 160, "start_date": "2026-02-25", "completion_date": "2027-06-26", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-11-15T04:35:28.747Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07437105" }, { "nct_id": "NCT02953314", "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "TEZ", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 83, "start_date": "2016-11", "completion_date": "2018-09", "has_results": true, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-11-15T04:35:28.747Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02953314" }, { "nct_id": "NCT04056702", "title": "Impact of Triple Combination CFTR Therapy on Sinus Disease.", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Elexacaftor-tezacaftor-ivacaftor exposure", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jennifer Taylor-Cousar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 31, "start_date": "2019-09-05", "completion_date": "2022-07", "has_results": false, "last_update_posted_date": "2021-03-11", "last_synced_at": "2026-11-15T04:35:28.747Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04056702" }, { "nct_id": "NCT03447249", "title": "A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-659/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 385, "start_date": "2018-03-07", "completion_date": "2019-02-05", "has_results": true, "last_update_posted_date": "2020-03-13", "last_synced_at": "2026-11-15T04:35:28.747Z", "location_count": 48, "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03447249" }, { "nct_id": "NCT06299709", "title": "A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VNZ/TEZ/D-IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 34, "start_date": "2024-03-13", "completion_date": "2024-05-23", "has_results": false, "last_update_posted_date": "2025-09-26", "last_synced_at": "2026-11-15T04:35:28.747Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06299709" }, { "nct_id": "NCT07283770", "title": "Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-581", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "D-IVA", "type": "DRUG" }, { "name": "TEZ", "type": "DRUG" }, { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 152, "start_date": "2025-12-09", "completion_date": "2027-07-12", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-15T04:35:28.747Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07283770" }, { "nct_id": "NCT04038710", "title": "Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Triple combination therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Jewish Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 8, "start_date": "2019-09-05", "completion_date": "2021-02-26", "has_results": false, "last_update_posted_date": "2021-03-11", "last_synced_at": "2026-11-15T04:35:28.747Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04038710" }, { "nct_id": "NCT07148739", "title": "Ensuring Access to Optimal Therapy in CF: The ENACT Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cystic Fibrosis (CF)" ], "interventions": [ { "name": "Elexacaftor / Ivacaftor / Tezacaftor", "type": "DRUG" }, { "name": "therapeutic drug monitoring", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Arkansas Children's Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 100, "start_date": "2025-06-10", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-11-15T04:35:28.747Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Seattle, Washington", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07148739" } ] }